Abstract:Toxoplasma gondii is an intracellular protozoan parasite that infects all nucleated cells except the red blood cells. Currently, nucleic acid vaccines are being widely investigated in Toxoplasma gondii control, and several nucleic acid vaccine candidate antigens have shown good protection in various studies. The aim of this study was to construct a nucleic acid vaccine with Toxoplasma gondii SRS29C as the target gene. We explored the nucleic acid vaccine with Toxoplasma surface protein SRS29C and the combined gene of SRS29C and SAG1 and evaluated its immunoprotective effect against Toxoplasma gondii. To amplify the gene fragment and clone it to the expression vector, the recombinant plasmid pEGFP-SRS29C was constructed by PCR. Eukaryotic cells were transfected with the plasmid, and the expression of the target protein was assessed using the Western blot method. The level of serum IgG was determined via ELISA, and the splenic lymphocyte proliferation ability was detected using the CCK-8 method. The percentages of CD4+ and CD8+ T cells were measured by flow cytometry. Mice were immunised three times with single-gene nucleic acid vaccine and combination vaccine. Splenic lymphocytokine expression was determined using ELISA kits. The mice's survival time was monitored and recorded during an in vivo insect assault experiment, and the vaccine's protective power was assessed. The outcomes showed that PCR-amplification of an SRS29C gene fragment was successful. The 4,733-bp vector fragment and the 1,119-bp target segment were both recognised by double digestion. Additionally, after transfection of the recombinant plasmid pEGFP-SRS29C, Western blot examination of the extracted protein revealed the presence of a target protein strip at 66 kDa. The test results demonstrated that the IgG content in the serum of the pEGFP-SRS29C group and the co-immunization group was significantly higher than that of the PBS group and the empty vector group. The IgG potency induced by the co-immunization group was higher than that of the pEGFP-SRS29C group and the pEGFP-SAG1 group, the number of splenic lymphocyte proliferation number was higher than that of the PBS group and the empty vector group. The CD4+/CD8+ T ratio was higher than that of the PBS group and the empty vector group. The expression of IFN-γ and TNF-α in the splenocytes of the pEGFP-SRS29C group and the combined immunisation group was significantly higher following antigen stimulation. In the worm attack experiments, mice in the PBS and empty vector groups perished within 9 days of the worm attack, whereas mice in the pEGFP-SRS29C group survived for 18 days, mice in the pEGFP-SAG1 group survived for 21 days, and mice in the co-immunization group survived for 24 days. This demonstrates that the constructed Toxoplasma gondii nucleic acid vaccine pEGFP-SRS29C and the combined gene vaccine can induce mice to develop certain humoral and cellular immune responses, and enhance their ability to resist Toxoplasma gondii infection.

Construction and identification of a recombinant Mycobacterium smegmatis vaccine expressing the Plasmodium vivax pvMSP1-19 gene

[Construction and Evaluation of a Tuberculosis Multistage Vaccine Candidate Based on Recombinant Listeria Ivanovii].

Expression,purification and initial identification of the multi-epitope gene of Plasmodium vivax in Pichia pastoris

A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles

Construction of a Vaccinia Virus Vectored Multi-Epitope Vaccine Candidate for Plasmodium Falciparum

Construction of Pmsl As a New Vector for Overexpressing Recombinant Proteins in Mycobacteria

The Preparation of Mycobacterium Tuberculosis HSP65 DNA Vaccine and the Prokaryotic Expression of the Recombinant HSP65 Protein

Recombinant Expression,Purification and Identification of Antigen Rv0173 of Mycobacterium Tuberculosis(mtb.)

Recombinant Expression, Purification and Identification of Antigen Rv0309 of Mycobacterium Tuberculosis

Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein of Plasmodium vivax in murine model

Prokaryotic cell expression of the surface antigen 1 gene from GJS strain of Toxoplasma gondii and its antigenicity analysis

Anti-Plasmodium vivax merozoite surface protein 3 Υ (PvMSP3 Υ) antibodies upon natural infection

Recombinant Expression and Purification of Antigen 85A of Mycobacterium Tuberculosis(Mtb.)

Development of Mycobacterial Inducible Expression System and Application for Immunological Diagnostics on Tuberculosis

Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites

Evaluation of transmission-blocking potential of Pv22 using clinical Plasmodium vivax infections and transgenic Plasmodium berghei

Oral vaccination of mice against rodent malaria with recombinant Lactococcus lactis expressing MSP-1(19).

Construction of Toxoplasma gondii SRS29C nucleic acid vaccine and comparative immunoprotective study of an SRS29C and SAG1 combination

The Construction and Sub-Cellular Localization Analysis of Novel Mycobacterial Membrane-Anchored Expression Vector

Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45

Evaluation of transmission-blocking potential of PvPSOP25 using transgenic murine malaria parasite and clinical isolates